ReviewInternational journal of urology : official journal of the Japanese Urological Association2026
Rationale for the Use of 8-Aminoguanine for the Management of Cystitis.
Review in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Bladder pain and associated lower urinary tract symptoms (LUTSs) are hallmark features of interstitial cystitis/bladder pain syndrome (IC/BPS) and hemorrhagic cystitis (HC). IC/BPS is characterized by bladder-based pain and irritative bladder symptoms, with or without gross inflammatory changes (Hunner lesions) in the bladder wall, and the absence of well-described causes such as infection or neoplastic disease. The clinical features of HC are similar to IC/BPS, but in this instance, they are always associated with visible inflammatory disease with known etiologies such as infection or a complication of radiation and/or chemotherapy. While progress has been made in defining the spinal circuits that gate pain signals emanating from the pelvic viscera, lack of a clear understanding of the mechanisms leading to cystitis-induced visceral pain and lack of validated therapeutic targets for cystitis are a source of frustration for clinicians treating conditions such as IC/BPS and HC and their patients. This review will focus on an emerging therapy for cystitis, namely 8-aminoguanine (8-AG), which inhibits the enzyme purine nucleoside phosphorylase (PNPase). PNPase is important for metabolism of "tissue-protective" purine metabolites into "tissue-damaging" purines that generate free radicals. IC/BPS patients without and with Hunner lesions exhibit a dysregulation of purine metabolism, with elevated levels of urotoxic purine metabolites compared to healthy controls. Rodents treated with cyclophosphamide are a standard animal model for cystitis and exhibit multiple abnormalities, including increased urinary frequency, neural mechanosensitivity, suppression of pain-reducing purines, and increased urothelial inflammation/damage. Orally administered 8-AG prevents all observed histological, structural, biochemical, and physiological abnormalities in cyclophosphamide-induced cystitis. These findings demonstrate that 8-AG holds promise for reducing pain and preventing bladder damage for patients with cystitis-associated pain and LUTS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.